TOKYO -- Japanese materials manufacturer AGC will boost production by 50% of a crucial agent in a coronavirus vaccine candidate under development by U.S. firm Novavax.
Subsidiary AGC Biologics, based in the U.S. city of Seattle, agreed to supply enough of the adjuvant component for billions of doses in 2020 and 2021. Adjuvants are agents that induce the production of antibodies, improving the individual's immune response.
